Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies
about
Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbensThe serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogenRobust optimization of SVM hyperparameters in the classification of bioactive compoundsMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsAVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.5-hydroxytryptamine 2C receptors in the dorsal striatum mediate stress-induced interference with negatively reinforced instrumental escape behavior.5-HT2C receptors in the basolateral amygdala and dorsal striatum are a novel target for the anxiolytic and antidepressant effects of exerciseThe loss of methyl-CpG binding protein 1 leads to autism-like behavioral deficits.Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling.Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in miceGq/5-HT2c receptor signals activate a local GABAergic inhibitory feedback circuit to modulate serotonergic firing and anxiety in miceImpact of RNA editing on functions of the serotonin 2C receptor in vivoSerotonin 2c receptor RNA editing in major depression and suicide.Serotonin Receptor 2C -759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients.A unique gene expression signature associated with serotonin 2C receptor RNA editing in the prefrontal cortex and altered in suicideFunctional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors.Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjectsDependencies among editing sites in serotonin 2C receptor mRNA.Could agomelatine be the ideal antidepressant?Iloperidone, asenapine and lurasidone: a primer on their current status.Fine-tuning serotonin2c receptor function in the brain: molecular and functional implicationsDepression in vascular pathologies: the neurologist's point of view.Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophreniaDrug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formationRole for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures.Genotype-Dependent Difference in 5-HT2C Receptor-Induced Hypolocomotion: Comparison with 5-HT2A Receptor Functional Activity.L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex.Serotonin receptor signaling and regulation via β-arrestins.Differential effects of acute and repeated citalopram in mouse models of anxiety and depressionThe effects of pharmacological modulation of the serotonin 2C receptor on goal-directed behavior in micePhysical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling.Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response modelAddressing circadian rhythm disturbances in depressed patients.Agomelatine for Depression in Schizophrenia: A Case-SeriesCircuits Regulating Pleasure and Happiness-Mechanisms of Depression.Affect-related behaviors in mice misexpressing the RNA editing enzyme ADAR2.Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.
P2860
Q24596784-27586C48-0D15-4BE1-938C-88BD96EDFADFQ24620468-D1ED024A-6D7F-49AC-8E13-C2D5366C165DQ27902297-4541BEAF-EE56-408F-AF57-624CC0508E2CQ28066691-5DBD46C0-2734-4161-A614-C32BD99AB5D0Q28305100-B66E2B01-31D2-4E05-BED6-DB83F5A8A268Q30377178-5FFE51FB-95A7-46DD-B1A6-1884EE4B6634Q30460367-144474F8-B45C-4DEC-8648-61BBA2C63583Q30462731-A3839CC3-2F0B-43E6-8C93-68FDEF88AF81Q30488542-43B60770-1352-4293-99E9-4D8E9E400FA8Q30493133-A35B63CC-900F-4F0B-A31B-6A61B1B7CCDEQ30494303-3F834CBB-5404-4389-AAA8-4D5ED03FB153Q30843872-272350C2-0127-4385-ADEC-A4ED0A7229F8Q33674169-FB2E18F7-6E6D-4828-A76B-C2D20B9A0176Q33806232-C6F9E99F-2C23-4855-B06F-1B94C59F946AQ33997373-F7748A5D-65F4-4B0A-9CDC-4D27564A4D4EQ34012293-3270BB18-2B9D-414F-BDBA-FE5490BF674CQ34074496-8191ED53-61A0-45BC-827C-F9606834BDA7Q34158784-0F9F1C36-F21D-494B-A570-CD172ED14BC0Q34254887-AEBDA0EA-1659-4CF2-B7DF-BBBB68B8FD74Q34411825-C287E562-0DAA-489E-8305-5FA76F59E1F1Q34572999-26875059-7004-4E18-B65F-FCE8A2D0254BQ34641024-65E664F5-0ABC-4CD1-A182-0700BC301FE5Q35072763-322B37C4-29A5-40C5-B454-81187368C8B2Q35122942-2A3CD47C-58C5-47AA-AB13-834785FB5919Q35207454-4049DC81-ABCF-4872-B635-05D9069D9E59Q35573424-C305FC28-6BA5-4DBB-BF78-5AFC6EFCD373Q35991747-A71B33DF-1151-4A77-8D3C-E8E13590DEFDQ36038551-AE5A8EEC-9D71-4B88-A0C7-21FC8052B5F5Q36087200-74CEAB81-BB10-4BEA-BFB6-311361D764BAQ36126606-907B014F-A320-4EAA-8FCF-AABFF2840D24Q36647024-09386783-D85D-4243-ADA0-E9A4A3564651Q36822753-51E06E20-EB32-4D12-AAEF-71A1A49B2122Q36930837-1463B8D6-C862-4327-96DE-51A22FD680B8Q36954117-BD8F34CB-3D69-4261-813D-7D17DA0751A9Q37125668-E202A059-E562-4992-952A-AFBA582AEC80Q37254739-DDCB2D38-7233-45ED-9DB5-0546D5BCACE2Q37299879-891F9C5A-BC38-46E9-BE0F-52C2660C6DD7Q37405040-43DD47CD-CC56-43EC-98C5-8B529F225413Q37423436-6510D4B3-5650-4D43-BDA2-4E83E733B434Q37671124-BA631FE6-F4F7-4BD4-92D5-D23624DB6706
P2860
Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@ast
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@en
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@nl
type
label
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@ast
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@en
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@nl
prefLabel
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@ast
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@en
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@nl
P3181
P356
P1433
P1476
Serotonin 5-HT2C receptors as ...... n novel therapeutic strategies
@en
P2093
Mark John Millan
P304
P3181
P356
10.2515/THERAPIE:2005065
P407
P577
2005-01-01T00:00:00Z